SGP Stock Chart & Stats
$24.94
--
Market closed
$24.94
--
Day’s Range― - ―
52-Week Range$17.06 - $32.44
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$708.12M
Enterprise Value$371.19M
Total Cash (Recent Filing)$251.00M
Total Debt (Recent Filing)$1.61M
Price to Earnings (P/E)―
Beta0.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,433,353
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-8.93
Price to Sales (P/S)0.00
P/FCF Ratio-26.35
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-694.17
Enterprise Value/Ebitda-14.37
Forecast
1Y Price Target
$47.00Price Target Upside88.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SGP FAQ
What was SpyGlass Pharma’s price range in the past 12 months?
SpyGlass Pharma lowest stock price was $17.06 and its highest was $32.44 in the past 12 months.
What is SpyGlass Pharma’s market cap?
SpyGlass Pharma’s market cap is $708.12M.
When is SpyGlass Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SpyGlass Pharma’s earnings last quarter?
Currently, no data Available
Is SpyGlass Pharma overvalued?
According to Wall Street analysts SpyGlass Pharma’s price is currently Undervalued.
Does SpyGlass Pharma pay dividends?
SpyGlass Pharma does not currently pay dividends.
What is SpyGlass Pharma’s EPS estimate?
SpyGlass Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpyGlass Pharma have?
SpyGlass Pharma has 33,433,353 shares outstanding.
What happened to SpyGlass Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SpyGlass Pharma?
Currently, no hedge funds are holding shares in SGP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SpyGlass Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
SpyGlass Pharma
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
SGP Stock 12 Month Forecast
Average Price Target
$47.00
▲(88.45% Upside)